⚠ STRICT REGULATORY DIRECTIVE: B2B API SUPPLY ONLY

Shaanxi Sunrise Pharmaceutical Co., Ltd. operates strictly as an industrial API supplier. The Ivermectin (CAS: 70288-86-7) technical data provided below is exclusively directed at Veterinary Formulators, QA/QC Directors, and Procurement Managers. This raw material is intended for R&D, laboratory, and commercial manufacturing scale-up only. It is NOT a finished drug product and is strictly prohibited for direct human or animal consumption.

If you have spent any time in veterinary pharmaceutical procurement, you know that some molecules are flashes in the pan, while others become structural industry legends. Ivermectin is a masterpiece of evolutionary disruption. Derived from a single actinomycete soil sample (Streptomyces avermitilis), this macrocyclic lactone redefined the economic viability of global livestock management.

At Shaanxi Sunrise, we do not treat Ivermectin as a mere commodity powder. Whether your pipeline targets high-density bovine feedlots, swine integrations, or high-value companion animal preventatives, understanding the exact pharmacokinetics, isomeric ratios, and stability parameters behind its efficacy is what separates a top-tier veterinary manufacturer from a generic chemical broker. Stop formulating blind. Demand analytical predictability.

In veterinary parasitology, formulators constantly chase the elusive "all-in-one" solution. Most anthelmintics suffer from narrow therapeutic windows. Ivermectin is one of the rare true endectocides. It chemically targets both nematodes (internal gastrointestinal roundworms, lungworms) and arthropods (external mites, ticks, grubs, and lice) with equal lethality.

From a formulation standpoint, this broad-spectrum dominance stems from its extreme affinity for invertebrate nerve cells rather than specific metabolic pathways. For the B2B buyer, this means your finished dosage form offers commercial ranchers a simplified, high-margin treatment protocol. Instead of compounding three different active ingredients into a suspension, your clients deliver one powerful subcutaneous injection or topical pour-on. If an agricultural parasite possesses a nervous system and threatens livestock yields, Ivermectin is its terminal threat.

Let us rigorously audit the lipophilicity of CAS 70288-86-7. This is not just theoretical chemistry; it is the exact mechanism driving massive profitability for commercial livestock operators. Unlike highly water-soluble drugs (such as levamisole) that are rapidly metabolized and excreted through the renal system, Ivermectin is inherently lipophilic (fat-dwelling).

"Once administered, Ivermectin rapidly partitions into the host animal’s adipose tissue, creating a sustained biological reservoir. This slow-release pharmacokinetic profile guarantees the API continues to circulate at therapeutic plasma levels for weeks after the initial dosing event."

The clinical and financial translation? Fewer gathering and chute events for cattle, drastically reduced animal handling stress, and slashed labor costs. Furthermore, by clearing the gastrointestinal tract of nutritional thieves, the host animal directs 100% of its dietary intake toward muscle hypertrophy. In technical field trials, the Average Daily Gain (ADG) improvements following clinical-grade Ivermectin administration routinely outpace generic dewormers. You are formulating an economic advantage.

Here is where generic brokers fail. Ivermectin is not a single homologous molecule. It is a highly specific mixture of two chemically homologous compounds: 22,23-dihydroavermectin B1a (C₄₈H₇₄O₁₄) and 22,23-dihydroavermectin B1b (C₄₇H₇₂O₁₄). The biological efficacy is heavily driven by the larger B1a fraction.

Substandard manufacturing fermentation and catalytic hydrogenation processes result in depressed B1a levels and elevated unknown impurities. According to strict USP and EP monographs, commercial-grade Ivermectin API must contain no less than 90.0% of the B1a component, and the sum of B1a plus B1b must be no less than 95.0%. When you procure from Shaanxi Sunrise, our High-Performance Liquid Chromatography (HPLC) release testing guarantees the B1a fraction consistently exceeds 95.0%. We minimize the B1b and related substance drag, ensuring your final injection solutions remain potent, stable, and highly viscous without precipitating in the vial.

The pharmacological execution occurs at the glutamate-gated chloride channels (GluCls) located within the invertebrate nervous and muscle systems. The degradation pathway follows a precise sequence:

• Step 1 (High-Affinity Binding): Ivermectin molecules bind to GluCls with extreme tenacity, locking them permanently in the "open" structural conformation.

• Step 2 (Ionic Influx): A massive, uncontrollable influx of chloride ions floods the intracellular space.

• Step 3 (Hyperpolarization): The parasite's nerve and muscle cells become totally hyperpolarized, preventing the transmission of action potentials.

• Step 4 (Flaccid Paralysis): The parasite loses all ability to move, attach to the intestinal wall, feed, or reproduce, resulting in flaccid paralysis and rapid death.

Because mammalian hosts have their central nervous system GABA receptors safely shielded behind a robust, impermeable Blood-Brain Barrier (BBB), the API remains exceptionally safe for the host animal while acting as a terminal neurotoxin for the invading parasite.

Developing a 1% w/v Ivermectin subcutaneous injection requires precise excipient compatibility. Ivermectin is highly insoluble in water. Formulators must utilize non-aqueous solvent systems, typically a precisely balanced matrix of Propylene Glycol and Glycerol Formal. If the API contains high moisture content (Loss on Drying > 1.0%), it will trigger hydrolysis and clouding within the solvent matrix over the 24-month shelf life.

Furthermore, the macrocyclic lactone ring is highly susceptible to ultraviolet (UV) photodegradation. Exposure to direct light rapidly degrades the B1a active component into inactive isomers. We protect your procurement chain by packaging our API exclusively in pharmaceutical-grade, opaque, double-layered aluminum foil vacuum bags, completely shielding the crystal lattice from UV radiation during global maritime or air transit.

Authentic formulation science requires rigorous risk management. We mandate our procurement partners understand the biochemical limits of this API:

In a global market flooded with cheap, degraded macrocyclic lactones that fail baseline stability testing, the origin of your API dictates your market survival and regulatory compliance. At Shaanxi Sunrise Pharmaceutical Co., Ltd., we back our commercial Ivermectin batches with exhaustive HPLC documentation, residual solvent mapping, and strict adherence to the latest USP and EP veterinary monographs.

Do not compromise your veterinary parenteral formulations with untraceable chemicals. Contact the Shaanxi Sunrise technical engineering team today to secure veterinary-grade Ivermectin API, request samples for your pilot batch, and audit our comprehensive Certificates of Analysis (CoA).

• FDA Database: CVM GFI #113 - Ivermectin Products for Animal Use.

• Merck Veterinary Manual: Macrocyclic Lactones Overview & Pharmacokinetics.

• USP-NF Archive: Ivermectin Monograph (Current Edition).

• Springer Literature: Campbell, W. C. (1989). Ivermectin and Abamectin.